{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:33:00Z","timestamp":1793244780866,"version":"4.5.0"},"reference-count":45,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The risk of venous thrombosis (VT) varies according to the type of progestogen that is found in combined oral contraceptives (COCs). When combined with the estrogen component ethinylestradiol (EE), the androgenic progestogens are better able to counteract the EE-induced stimulation of liver proteins and hence are associated with a twofold decreased risk of VT compared with non- or antiandrogenic progestogens, which exert limited counteraction of EE. Because EE is responsible for the increased risk, novel estrogens such as estradiol were developed and seem to have a lower risk of VT than EE. Besides COCs, there are other methods of hormonal contraceptives, such as progestogen-only contraceptives, which do not increase VT risk, except for injectables. Other nonoral contraceptives are combined vaginal rings and patches. There is insufficient evidence regarding the risk of VT associated with these two methods compared with COCs. The increased risk associated with COCs is more pronounced in women with inherited thrombophilia. In these women, the progestogen levonorgestrel seems to be associated with the lowest risk of VT. Currently, there are no studies that have investigated the risk of VT in women who switch COCs. We hypothesize that switching COCs, even when switching from a high- to a low-risk COC, increases the risk of VT. Finally, risk prediction models in women who use COCs are lacking. Since there is a large number of VT cases associated with COC use, it is important to identify women at risk of VT and advise them on alternative contraception methods.<\/jats:p>","DOI":"10.1055\/s-0040-1715793","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T19:02:55Z","timestamp":1601924575000},"page":"865-871","source":"Crossref","is-referenced-by-count":45,"title":["Hormonal Contraceptives and the Risk of Venous Thrombosis"],"prefix":"10.1055","volume":"46","author":[{"given":"Deeksha","family":"Khialani","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"Rosendaal","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid van Hylckama","family":"Vlieg","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"h2135","DOI":"10.1136\/bmj.h2135","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"350","author":"Y Vinogradova","year":"2015","journal-title":"BMJ"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"I A Naess","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref4","first-page":"756","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"A T Cohen","year":"2007","journal-title":"Thromb Haemost"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(61)91061-3","article-title":"Pulmonary embolism","volume":"278","author":"W M Jordan","year":"1961","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/bmj.292.6519.526","article-title":"Oral contraceptives and venous thromboembolism: findings in a large prospective study","volume":"292","author":"M Vessey","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen","volume":"346","author":"K W Bloemenkamp","year":"1995","journal-title":"Lancet"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"B B Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ije\/21.1.48","article-title":"Risk factors for fatal venous thromboembolism in young women: a case-control study","volume":"21","author":"M Thorogood","year":"1992","journal-title":"Int J Epidemiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"J P Vandenbroucke","year":"1994","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease","volume":"346","author":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","year":"1995","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(96)07496-X","article-title":"Population-based study of risk of venous thromboembolism associated with various oral contraceptives","volume":"349","author":"R D Farmer","year":"1997","journal-title":"Lancet"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0002-9378(97)70289-8","article-title":"Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation","volume":"177","author":"J P Vandenbroucke","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis","volume":"323","author":"J M Kemmeren","year":"2001","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"B H Stegeman","year":"2013","journal-title":"BMJ"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13625180600772741","article-title":"Metabolic and clinical effects of progestogens","volume":"11","author":"I Wiegratz","year":"2006","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"S N Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/IJWH.S22645","article-title":"Estradiol valerate and dienogest: a new approach to oral contraception","volume":"3","author":"J W Kiley","year":"2011","journal-title":"Int J Womens Health"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2147\/PPA.S39371","article-title":"Nomegestrol acetate-17b-estradiol for oral contraception","volume":"7","author":"A Burke","year":"2013","journal-title":"Patient Prefer Adherence"},{"issue":"S 01","key":"ref21","first-page":"i78","volume":"23","author":"S Parke","year":"2008"},{"key":"ref22","first-page":"3","article-title":"Metabolic effects of a new four-phasic oral contraceptive containing estradiol valerate and dienogest","volume":"111","author":"S Parks","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1538-7836.2012.04720.x","article-title":"Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives","volume":"10","author":"M Raps","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/humrep\/deh612","article-title":"Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens","volume":"20","author":"H AAM van Vliet","year":"2005","journal-title":"Hum Reprod"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jth.12172","article-title":"Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial","volume":"11","author":"M Raps","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"J Dinger","year":"2016","journal-title":"Contraception"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/OAJC.S179673","article-title":"Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives?","volume":"9","author":"F Fruzzetti","year":"2018","journal-title":"Open Access J Contracept"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/13625187.2011.604450","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17\u03b2-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism","volume":"16","author":"U M \u00c5gren","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH10-05-0327","article-title":"Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate\/17\u03b2-estradiol, compared with those of levonorgestrel\/ethinyl estradiol. A double-blind, randomised study","volume":"105","author":"P Gaussem","year":"2011","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.contraception.2016.04.014","article-title":"Progestin-only contraception and thromboembolism: a systematic review","volume":"94","author":"N K Tepper","year":"2016","journal-title":"Contraception"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/2047487318774847","article-title":"Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis","volume":"25","author":"M Glisic","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"S 01","key":"ref32","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.maturitas.2003.09.016","article-title":"Differential effects of progestins on hemostasis","volume":"46","author":"A E Schindler","year":"2003","journal-title":"Maturitas"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0889-8545(21)00583-0","article-title":"Nonoral routes of estrogen administration","volume":"14","author":"M I Cedars","year":"1987","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.contraception.2016.10.005","article-title":"Nonoral combined hormonal contraceptives and thromboembolism: a systematic review","volume":"95","author":"N K Tepper","year":"2017","journal-title":"Contraception"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.fertnstert.2016.09.027","article-title":"Combined hormonal contraception and the risk of venous thromboembolism: a guideline","volume":"107","year":"2017","journal-title":"Fertil Steril"},{"issue":"07","key":"ref36","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/jth.13349","article-title":"Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis","volume":"14","author":"E F van Vlijmen","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13625180008500383","article-title":"Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?","volume":"5","author":"M Spannagl","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1055\/s-0038-1641152","article-title":"Type of combined contraceptives, factor V Leiden mutation and risk of venous thromboembolism","volume":"118","author":"J Hugon-Rodin","year":"2018","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/ije\/10.4.383","article-title":"Biological models and statistical interactions: an example from multistage carcinogenesis","volume":"10","author":"J Siemiatycki","year":"1981","journal-title":"Int J Epidemiol"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrg2579-c2","article-title":"Statistical interaction in human genetics: how should we model it if we are looking for biological interaction?","volume":"12","author":"X Wang","year":"2011","journal-title":"Nat Rev Genet"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"A van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16666","article-title":"The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk","author":"D Khialani","year":"2020","journal-title":"Br J Haematol"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0037-1613960","article-title":"A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways","volume":"84","author":"G Tans","year":"2000","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref47","doi-asserted-by":"crossref","first-page":"e0182041","DOI":"10.1371\/journal.pone.0182041","article-title":"Risk prediction of developing venous thrombosis in combined oral contraceptive users","volume":"12","author":"A McDaid","year":"2017","journal-title":"PLoS One"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/archinternmed.2008.589","article-title":"The value of family history as a risk indicator for venous thrombosis","volume":"169","author":"I D Bezemer","year":"2009","journal-title":"Arch Intern Med"},{"issue":"09","key":"ref49","doi-asserted-by":"crossref","first-page":"e1001515","DOI":"10.1371\/journal.pmed.1001515","article-title":"Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis","volume":"10","author":"Y-J Cheng","year":"2013","journal-title":"PLoS Med"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"W Ageno","year":"2008","journal-title":"Circulation"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1715793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T01:32:07Z","timestamp":1669080727000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1715793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":45,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2020,12,23]]},"published-print":{"date-parts":[[2020,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1715793","relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,5]]}}}